Abstract | OBJECTIVE: METHODS: The study cohort comprised 200 patients with sleep and mood disorders during recovery from COVID-19. Patients were randomized into the control group and the experimental group in a 1:1 ratio by blocked randomization. The patients received either Xiaoyao capsule (experimental group) or a placebo Xiaoyao capsule (control group) for 2 weeks. The improvements in the Traditional Chinese Medicine (TCM) syndrome scales, total effective rates, and disappearance rates of irritability, anxiety, and poor sleep were compared between the two groups. RESULTS: The TCM syndrome pattern scales, total effective rates, and disappearance rates of irritability, anxiety, and poor sleep did not significantly differ between the experimental group versus the control group in the full analysis set and the per protocol set after 1 and 2 weeks of treatment ( > 0.05). CONCLUSIONS:
|
Authors | Yang Cunqing, Lian Fengmei, Yang Guiping, Huang Yufeng, Zhang Shuangbin, Wang Jianghua, Zhou Jing, Guo Dongqing, Shen Chuanyun, Y E Tiansong, F U Aojie, L I Xiaoli, Chen Le, Zhang Huifeng, T U Qiyin, Wang Ying, Yang Wenzhe, Tong Xiaolin, B A Yuanming |
Journal | Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
(J Tradit Chin Med)
Vol. 43
Issue 2
Pg. 343-351
(04 2023)
ISSN: 2589-451X [Electronic] China |
PMID | 36994523
(Publication Type: Randomized Controlled Trial, Journal Article)
|
Chemical References |
- xiaoyao
- Drugs, Chinese Herbal
|
Topics |
- Humans
- COVID-19
- Drugs, Chinese Herbal
(therapeutic use)
- Mood Disorders
(drug therapy)
- Sleep Initiation and Maintenance Disorders
(drug therapy)
- Treatment Outcome
|